2. Signaling Pathways
  3. Immunology/Inflammation
  4. CTLA-4

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4; CD152

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is an inhibitory receptor belonging to the CD28 immunoglobulin subfamily. CTLA-4 is expressed primarily by T cells. The ligands of CTLA-4, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. The interactions of the ligands with CTLA-4 serve to inhibit T cell responses. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and self-tolerance. The mechanisms by which CTLA-4 exerts its inhibitory function can be categorized as either cell-intrinsic (affects the CTLA-4 expressing T-cell) or cell-extrinsic (affects secondary cells). CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9901
    Ipilimumab
    		Inhibitor 99.88%
    Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.
    Ipilimumab
  • HY-108829
    Abatacept
    		≥99.0%
    Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
    Abatacept
  • HY-P9918
    Tremelimumab
    		99.50%
    Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.
    Tremelimumab
  • HY-P99132
    Anti-Mouse CTLA-4 Antibody (9D9)
    		≥98.0%
    Anti-Mouse CTLA-4 Antibody is an anti-mouse CTLA-4 IgG2b antibody inhibitor derived from host mouse.
    Anti-Mouse CTLA-4 Antibody (9D9)
  • HY-P99166
    Vudalimab
    		Inhibitor 99.90%
    Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.
    Vudalimab
  • HY-P990042
    Gotistobart
    		Inhibitor 98.00%
    Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment.
    Gotistobart
  • HY-P990041
    Firastotug
    		Inhibitor
    Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer.
    Firastotug
  • HY-P990048
    Muzastotug
    		Inhibitor
    Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic.
    Muzastotug
  • HY-P99484
    Botensilimab
    		Inhibitor
    Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer.
    Botensilimab
  • HY-P99844
    Davoceticept
    Davoceticept (ALPN-202; CD80 vIgD-Fc) is a monoclonal antibody targeting CTLA-4. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells.
    Davoceticept
  • HY-P99514
    Zalifrelimab
    		Inhibitor
    Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.
    Zalifrelimab
  • HY-P99809
    Quavonlimab
    		Inhibitor ≥99.0%
    Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody.
    Quavonlimab
  • HY-P99760
    Nurulimab
    		Inhibitor
    Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma.
    Nurulimab
  • HY-P99540
    Tuvonralimab
    		Inhibitor 99.14%
    Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab.
    Tuvonralimab
  • HY-P990080
    Sovipostobart
    		Inhibitor
    Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic.
    Sovipostobart
  • HY-P99714
    Lorigerlimab
    		Inhibitor
    Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
    Lorigerlimab
  • HY-108829A
    Abatacept (powder)
    		Inhibitor
    Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
    Abatacept (powder)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity